Adlai Nortye Ltd. American Depositary Shares (ANL) Stock
Key stats
- Market cap
- $698.72M
- Price / Earnings ratio
- -28.5x
- EPS (TTM)
- -$0.66
- Volume
- Loading
- 52-week high
- $17.25
- 52-week low
- $0.88
Source: third-party data provider, as of November 13, 2026
Compare with ANL
Recent news

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
ANL

Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
ANL

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
ANL

Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
ANL
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.16
- MACD 12/26/9
- -0.80
- EMA 9 of MACD
- -1.01
- MACD histogram
- 0.21
- SMA 50
- $13.17
- Price below SMA 50
- EMA 50
- $12.09
- Price below EMA 50
- SMA 200
- $11.70
- Price below SMA 200
- EMA 200
- $10.39
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
ANL

Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
ANL

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's What You Should Know
ANL

Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
Here's Why Adlai Nortye Ltd. Sponsored ADR (ANL) Is a Great 'Buy the Bottom' Stock Now
ANL

IBRX Stock Notches Strongest Quarter Ever — But These 2 Smaller Biotech Plays Ran Even Hotter
IBRX Stock Notches Strongest Quarter Ever — But These 2 Smaller Biotech Plays Ran Even Hotter
ANL

Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
Adlai Nortye Ltd. Sponsored ADR (ANL) Upgraded to Buy: Here's Why
ANL

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year?
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year?
ANL

Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?
Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year?
ANL

U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap
U.S. IPO Weekly Recap: August Wraps Up With 1 Nano-Cap
ANL
News tone: automated (AI) classification of the article's content, not a price prediction.
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Yang Lu EMBA | Co- Founder, CEO & Chairman | 1979 |
| Mr. Donghui Yang | Chairman of the Greater China Region | — |
| Dr. Xiaofeng Ye Ph.D. | Chief Financial Officer | 1979 |
| Dr. Ngai Chiu Tse M.D., Ph.D. | President & Head of Research & Development | 1967 |
| Dr. Zhiyong Yu Ph.D. | Vice President of Operations | — |
| Mr. Chen Yang EMBA | Head of HR & Administration & Government Affairs | — |
| Dr. Nanhai He Ph.D. | Head of Discovery | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.16
- MACD 12/26/9
- -0.80
- EMA 9 of MACD
- -1.01
- MACD histogram
- 0.21
- SMA 50
- $13.17
- Price below SMA 50
- EMA 50
- $12.09
- Price below EMA 50
- SMA 200
- $11.70
- Price below SMA 200
- EMA 200
- $10.39
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $20.00
- Average
- $33.33
- High
- $49.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +62.8 | -15.2 | -16.0 | +80.6 | -23.0 | -4.4 | +22.6 | +9.2 | +17.4 | -39.4 | +15.8 |



